[
    [
        {
            "time": "",
            "original_text": "仿制药品目录建议清单出炉，受益股有哪些？",
            "features": {
                "keywords": [
                    "仿制药",
                    "目录",
                    "建议清单",
                    "受益股"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "仿制药品目录建议清单出炉，受益股有哪些？",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "复星医药：海外市场取得新突破，首个国产曲妥珠单抗获欧盟上市申请受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "海外市场",
                    "曲妥珠单抗",
                    "欧盟",
                    "上市申请"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：海外市场取得新突破，首个国产曲妥珠单抗获欧盟上市申请受理",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【健康界产业周刊】青蒿素“引爆”资本市场 百济神州与新基“分手”",
            "features": {
                "keywords": [
                    "健康界",
                    "青蒿素",
                    "资本市场",
                    "百济神州",
                    "新基",
                    "分手"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【健康界产业周刊】青蒿素“引爆”资本市场 百济神州与新基“分手”",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "东海证券发布医药行业中期策略：两维度布局",
            "features": {
                "keywords": [
                    "东海证券",
                    "医药行业",
                    "中期策略",
                    "两维度布局"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "东海证券发布医药行业中期策略：两维度布局",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "威高股份急挫逾4% 拟折让最多7%配售9170万股",
            "features": {
                "keywords": [
                    "威高股份",
                    "急挫",
                    "配售",
                    "9170万股"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "威高股份急挫逾4% 拟折让最多7%配售9170万股",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]